A longitudinal study of maternal plasma insulin-like growth factor binding protein-1 concentrations during normal pregnancy and pregnancies complicated by pre-eclampsia

• Published in: Human reproduction (Oxford) Vol. 15; no. 10; pp. 2215 - 2219
• Main Authors: Anim-Nyame, N., Hills, F.A., Sooranna, S.R., Steer, P.J., Johnson, M.R.
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.10.2000
• Subjects: Adult; Biological and medical sciences; Birth Weight; Blood Pressure; Diseases of mother, fetus and pregnancy; Female; Gynecology. Andrology. Obstetrics; Humans; implantation; Infant, Newborn; Insulin-Like Growth Factor Binding Protein 1 - blood; insulin-like growth factor binding protein-1; Longitudinal Studies; Maternal Age; Medical sciences; placentation; pre-eclampsia; Pre-Eclampsia - blood; Predictive Value of Tests; Pregnancy - blood; Pregnancy. Fetus. Placenta; Reference Values; Regression Analysis; trophoblast invasion; insulin-like growth factor binding protein-1; implantation; placentation; pre-eclampsia; trophoblast invasion; Human; Trophoblaste; Pregnancy disorders; Fetal membrane; Concentration; Pregnancy toxemia; Invasion; Pregnancy; Insulin like growth factor binding protein; Ovum implantation; Mother; Follow up study; Preeclampsia; Female
• ISSN: 0268-1161; 1460-2350; 1460-2350
• DOI: 10.1093/humrep/15.10.2215

Insulin-like growth factor binding protein-1 (IGFBP-1) is synthesized by the decidual stroma, and is thought to act locally to inhibit IGF activity and so limit trophoblast invasion. Cross-sectional studies have reported conflicting data on maternal circulating concentrations of IGFBP-1 in early pregnancy before the development of pre-eclampsia. A longitudinal study was performed in 10 women who went on to develop pre-eclampsia and a group of 12 normal pregnant controls, chosen to be similar for maternal age, booking body mass index (BMI) and gestational age. Maternal IGFBP-1 concentrations were measured in plasma obtained at 16, 20, 24, 28, 32 and 36 weeks. Plasma IGFBP-1 concentrations were unchanged over this period in normal pregnancy. In contrast, the concentrations in women who developed pre-eclampsia increased progressively. At 16, 20, and 24 weeks the concentrations were significantly lower compared to normal pregnancy, at 28 and 32 weeks, similar, but by 36 weeks the concentrations were significantly greater than the normal controls. The data show that circulating IGFBP-1 concentrations are lower in early pregnancy before the development of pre-eclampsia. Thus, it is suggested that IGFBP-1-induced inhibition of IGF activity is unlikely to be responsible for the impaired trophoblast invasion observed in pre-eclampsia.